Financial News

Pfizer 4Q Results

Growth of Eliquis and Xtandi partially offset by lower sales of Abrysvo, Xeljanz and Oncology biosimilars.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer 4Q Revenues: $17.8 billion (+22%) 4Q Earnings: $410 million (loss of $3.4 billion 4Q24) FY Revenues: $63.6 billion (+7%) FY Earnings: $8.0 billion (earnings were $2.1 billion FY24) Comments: Global Biopharmaceutical sales were $17.4 billion in the quarter, up 23%. Pfizer CentreOne sales were $325 million in the quarter, down 11%. Revenues in the quarter reflect an operational increase of $3.1 billion, or 21%, primarily due to a one-time, non-cash Paxlovid revenue reversal o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics